# Sarepta plunges 7.1% in biotech selloff

> Cambridge biotech firm caught in sector-wide downturn with no company-specific news driving the decline.
- Title: Sarepta plunges 7.1% in biotech selloff | Shortify
- Summary: Cambridge biotech firm caught in sector-wide downturn with no company-specific news driving the decline. Sarepta's sharp drop reflects broad investor…
- Keywords: sarepta therapeutics, srpt, biotech stocks, sector selloff, stock decline, market volatility, investor sentiment, Sarepta, plunges, biotech, selloff, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/sarepta-therapeutics-drops-7-1-amid-sector-wide-selling
- Author: AlphaStreet Newsdesk
- Published: 2026-09-23T15:34:07+00:00
- Read time: 1 min
- Topics: sarepta therapeutics, srpt, biotech stocks, sector selloff, stock decline, market volatility, investor sentiment
## Sarepta drops 7.1% in sector rout
Sarepta Therapeutics fell 7.1% on Wednesday to $19.33 as a broad biotech selloff swept through the sector with no company-specific news driving the decline.
## Peers post sharp losses too
Four biotech peers fell simultaneously: BHVN down 5.1%, RXRX down 4.9%, KOD down 6.5%, and VRDN down 3.2%, signaling sector-wide risk-off sentiment rather than isolated concerns.
## Market cap compressed to $2 billion
Trading volume hit 592,239 shares as the selloff left Sarepta with a $2.0 billion market capitalization, a significant compression for a company with approved therapies.
## Sarepta hit harder than peers
Sarepta's 7.1% decline outpaced most sector peers, suggesting the company faced particularly aggressive selling pressure or position unwinding during the session.
## Biotech faces rotating pressure
Sector volatility has persisted throughout 2026 as investors weigh clinical trial outcomes, regulatory decisions, and macroeconomic conditions against growth potential of novel therapies.
## Watch for stabilization signals
Investors should monitor whether sector weakness persists or stabilizes, and watch volume patterns to determine if Wednesday's selling represents capitulation or a broader retreat.
## Key takeaway

Sarepta's sharp drop reflects broad investor risk-off sentiment in biotech rather than problems with the company itself.